Synlogic announces achievement of proof of concept for synb8802 in enteric hyperoxaluria based on urinary oxalate lowering in phase 1b study

Results include -38% reduction in urinary oxalate compared to placebo in roux-en-y gastric bypass patients

SYBX Ratings Summary

SYBX Quant Ranking